Glenmark Pharmaceuticals, which has a manufacturing facility in Goa, announced that it has started studying the effect of its anti-viral drug FabiFlu on Covid-19 patients who have mild to moderate symptoms.
Glenmark has already completed phase 3 clinical trials with FabiFlu in mild to moderate Covid-19 patients and the results are expected shortly, the company said.
The drug firm also announced that lower production costs helped the company pass on the benefits to patients by reducing the price of the drug by 27% in India to Rs 75 per tablet. The drug was earlier priced at 103 per tablet.
On June 20, Glenmark said it received approval from the country’s drug regulator to manufacture and market FabiFlu to treat mild to moderate Covid-19 cases. The approval’s restricted use requires the patient consent before the treatment begins.